All In Biotech

Drug Trial Radar · NCT07424287

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

A Multicenter, Randomized, Open-label Phase III Clinical Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Investigator-selected Chemotherapy In Patients With BCG-unresponsive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC) (NiBladder 1)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 236 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

236

Planned (sponsor's estimate)

Start

Jul 13, 2026

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Sponsor type
Industry
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with BCG-unresponsive papillary-only non-muscle-invasive bladder cancer (NMIBC).

Conditions

  • NMIBC

Interventions

  • SHR-1501 for InjectionDrug

    SHR-1501 for injection.

  • BCG for InjectionDrug

    Bacillus calmette guerin (BCG) for injection.

  • Epirubicin Hydrochloride for InjectionDrug

    Epirubicin hydrochloride for injection.

  • Pirarubicin Hydrochloride for InjectionDrug

    Pirarubicin hydrochloride for injection.

  • Gemcitabine Hydrochloride for InjectionDrug

    Gemcitabine hydrochloride for injection.

  • Hydroxycamptothecin for InjectionDrug

    Hydroxycamptothecin for injection.

  • Mitomycin for InjectionDrug

    Mitomycin for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 5 years.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.